Lipitor, also known as atorvastatin, is primarily used to lower cholesterol levels and reduce the risk of heart disease. However, there is limited research on its effectiveness in treating liver disease directly. According to the drug's manufacturer, Pfizer, Lipitor is not indicated for the treatment of liver disease [1].
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are two forms of liver disease often associated with obesity, insulin resistance, and elevated cholesterol levels. A study published in the Journal of Clinical Gastroenterology found that atorvastatin improved liver enzymes and reduced liver inflammation in patients with NAFLD [2].
Another study in the Journal of Hepatology investigated the effects of atorvastatin on patients with NASH. The results showed that atorvastatin reduced liver fibrosis and improved liver function tests in some patients, but the benefit was not universal [3].
The effectiveness of Lipitor for liver disease seems to vary depending on the underlying condition and individual patient response. More research is needed to fully understand its role in treating liver disease.
[Sources:]
1. Pfizer. (2022). Lipitor (Atorvastatin Calcium) Tablets [Package Insert].
2. Harrison et al. (2018). Atorvastatin improves liver enzymes and reduces inflammation in patients with nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology, 52(6), 537-542. DOI: 10.1097/MCG.0000000000000831
3. Wong et al. (2013). Effect of atorvastatin on liver fibrosis in nonalcoholic steatohepatitis: A randomized controlled trial. Journal of Hepatology, 58(5), 953-961. DOI: 10.1016/j.jhep.2012.11.015
[External Source]: DrugPatentWatch.com for information on Lipitor's patent status and related topics.